1. Home
  2. FTK vs CTNM Comparison

FTK vs CTNM Comparison

Compare FTK & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flotek Industries Inc.

FTK

Flotek Industries Inc.

HOLD

Current Price

$16.88

Market Cap

522.1M

Sector

Industrials

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$12.63

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTK
CTNM
Founded
1985
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
522.1M
480.5M
IPO Year
1997
2024

Fundamental Metrics

Financial Performance
Metric
FTK
CTNM
Price
$16.88
$12.63
Analyst Decision
Buy
Buy
Analyst Count
1
4
Target Price
$20.00
$19.00
AVG Volume (30 Days)
201.9K
244.9K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
147.06
0.46
EPS
0.84
N/A
Revenue
$136,092,000.00
N/A
Revenue This Year
$13.33
N/A
Revenue Next Year
$16.38
N/A
P/E Ratio
$20.71
N/A
Revenue Growth
214.53
N/A
52 Week Low
$6.68
$3.35
52 Week High
$20.41
$16.33

Technical Indicators

Market Signals
Indicator
FTK
CTNM
Relative Strength Index (RSI) 53.87 43.79
Support Level $15.89 $11.54
Resistance Level $17.67 $13.26
Average True Range (ATR) 0.82 0.60
MACD 0.17 -0.02
Stochastic Oscillator 69.33 33.13

Price Performance

Historical Comparison
FTK
CTNM

About FTK Flotek Industries Inc.

Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: